Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes

Rhea-AI Summary

Century Therapeutics (NASDAQ: IPSC) secured an oversubscribed private placement expected to raise approximately $135 million in initial gross proceeds, led by TCGX with participation from RA Capital, Commodore Capital, Deep Track Capital, RTW, Venrock Healthcare Capital Partners and the T1D Fund.

The financing will issue ~117.39 million common shares (or pre-funded warrants) and warrants to purchase ~58.70 million shares at a purchase price of $1.15 per share, with accompanying warrants exercisable at $2.60. Full warrant exercise would provide an additional ~$153 million.

Century expects the offering to close on Jan 9, 2026, estimates the proceeds extend cash runway to Q1 2029, anticipates an IND submission in 2026 for CNTY-813 and initial clinical data in 2027. Proceeds are for development of CNTY-813 and general corporate purposes.

Positive

• Initial private placement of $135M in gross proceeds
• Financing led by new investor TCGX with top healthcare investors participating
• Estimated cash runway extended to Q1 2029
• Full warrant exercise could raise an additional $153M
• Clear timetable: IND submission 2026 and initial clinical data 2027

Negative

• Issuance of ~117.39M new shares may materially dilute existing shareholders
• Warrants exercisable at $2.60 could delay accretive capital until stock rises above strike
• Private placement priced near current levels, potentially signaling financing need to market

News Market Reaction – IPSC

+36.15% 11.4x vol

22 alerts

+36.15% News Effect

+32.0% Peak in 31 hr 57 min

+$45M Valuation Impact

$170M Market Cap

11.4x Rel. Volume

On the day this news was published, IPSC gained 36.15%, reflecting a significant positive market reaction. Argus tracked a peak move of +32.0% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $45M to the company's valuation, bringing the market cap to $170M at that time. Trading volume was exceptionally heavy at 11.4x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Private placement gross proceeds: $135 million Additional warrant proceeds: $153 million Common shares issued: 117,391,299 shares +5 more

8 metrics

Private placement gross proceeds $135 million Initial gross proceeds from private placement before fees

Additional warrant proceeds $153 million Potential gross proceeds on full warrant exercise

Common shares issued 117,391,299 shares Shares of common stock (or pre-funded warrants) in private placement

Warrants issued 58,695,648 warrants Accompanying warrants to purchase common stock (or pre-funded warrants)

Common share purchase price $1.15 per share Private placement price per share plus accompanying warrant

Pre-funded warrant price $1.1499 per pre-funded warrant Price per pre-funded warrant plus accompanying warrant

Pre-funded warrant exercise price $0.0001 per share Exercise price for pre-funded warrants, exercisable immediately

Warrant exercise price $2.60 per share Exercise price for common stock warrants; alternative $2.599 per pre-funded warrant

Market Reality Check

Price: $2.13 Vol: Volume 5,770,167 is 3.36x...

high vol

$2.13 Last Close

Volume Volume 5,770,167 is 3.36x the 20-day average of 1,719,422, showing elevated trading ahead of the financing news. high

Technical Shares at $1.30 were trading above the 200-day MA $0.57 and within 3% of the $1.34 52-week high.

Peers on Argus

IPSC was up 44.44% while close peers were mixed: BCAB -1.37%, BRNS +0.01%, PSTV ...

1 Up

IPSC was up 44.44% while close peers were mixed: BCAB -1.37%, BRNS +0.01%, PSTV +6.63%, RENB +19.33%, TPST +0.72%. Momentum scans showed only one biotech peer (ACRV) moving up, pointing to a company-specific reaction.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Board appointments	Positive	+3.8%	Added experienced biotech and capital-formation leaders to the board.
Nov 25	Conference participation	Neutral	+2.3%	Participation in Piper Sandler healthcare conference and fireside chat.
Nov 13	Earnings and update	Positive	-17.5%	Q3 2025 results, new CNTY-813 program and runway into 4Q 2027.
Nov 13	Program launch	Positive	-17.5%	Announcement of CNTY-813 beta islet program for Type 1 diabetes.
Oct 14	Conference presentation	Neutral	+1.8%	Planned presentation at Chardan’s 9th Annual Genetic Medicines Conference.

Pattern Detected

News tied to CNTY-813 and broader pipeline updates previously saw sharp selloffs, while conferences and governance updates had modest positive reactions.

Recent Company History

Over the last six months, IPSC news has centered on governance, conferences, and the launch of its Type 1 diabetes program CNTY-813. A Q3 2025 earnings and pipeline update on Nov 13, 2025 introduced CNTY-813 and extended cash runway but coincided with a -17.54% move, similar to the concurrent beta islet program announcement. In contrast, conference participation and board appointments in Oct–Dec 2025 produced modest gains of ~2–4%. Today’s large financing linked directly to CNTY-813 fits this pivot toward the diabetes franchise.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-10

The company has an active S-3 shelf registration dated 2025-07-10 that remains in effect through 2028-07-10, with no recorded usage to date in the provided context.

Market Pulse Summary

The stock surged +36.1% in the session following this news. A strong positive reaction aligns with a...

Analysis

The stock surged +36.1% in the session following this news. A strong positive reaction aligns with a sizeable capital raise that directly supports CNTY-813. The stock had moved 44.44% higher on volume over 3x its 20-day average and was trading near its $1.34 52-week high and well above the $0.57 200-day MA. Historically, major CNTY-813 updates saw sharp drawdowns, so sustained gains may depend on how investors weigh dilution against extended runway and future clinical milestones.

Key Terms

induced pluripotent stem cell (iPSC), pre-funded warrants, warrants, ind submission, +4 more

8 terms

induced pluripotent stem cell (iPSC) medical

"a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies"

Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, able to develop into many different cell types. Think of them as retrained workers who can be reassigned to multiple jobs; for investors they matter because iPSCs enable development of new therapies, personalized drug testing, and scaled cell products, which can drive long-term value but also face lengthy development timelines and regulatory scrutiny.

pre-funded warrants financial

"shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

warrants financial

"and accompanying warrants to purchase 58,695,648 shares of common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

ind submission regulatory

"an anticipated IND submission for CNTY-813 in 2026 and initial clinical data"

An IND submission is an application a drug developer files with a regulatory authority (for example, the U.S. Food and Drug Administration) asking permission to start testing a new medicine in humans. It shows the company’s lab and safety data and a plan for clinical studies; for investors, an accepted IND is like a green light to move from research to trials, reducing development risk and unlocking value milestones.

section 4(a)(2) of the securities act regulatory

"offered in a private placement under Section 4(a)(2) of the Securities Act of 1933"

A legal exemption that allows a company to sell securities directly to a limited group of buyers without registering the offering with the Securities and Exchange Commission. Think of it like a private sale among known parties rather than a public auction: it can speed fundraising and reduce disclosure requirements, but it also means less public information, lower liquidity and resale restrictions—factors investors should consider when weighing risk and exit options.

registration statement regulatory

"has agreed to file a registration statement with the Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

nasdaq rules regulatory

"conducted in accordance with applicable Nasdaq rules and was priced to satisfy"

Nasdaq rules are a set of guidelines and requirements that companies must follow to be listed and remain on the Nasdaq stock exchange. These rules help ensure companies are transparent, financially healthy, and operate fairly, which is important for investors to trust the market and make informed decisions. Think of them as the standards that keep the marketplace honest and organized.

private placement financial

"entered into a securities purchase agreement for a private placement for initial gross proceeds"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

AI-generated analysis. Not financial advice.

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses.

The financing is being led by new investor TCGX, and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, and the T1D Fund. The private placement is expected to close on January 9, 2026, subject to customary closing conditions.

“We believe this financing further enables our ambition to unlock the full potential of our lead product candidate, CNTY-813, a potentially curative beta islet cell program for Type 1 diabetes,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “We estimate this financing extends our cash runway to Q1 2029 with an anticipated IND submission for CNTY-813 in 2026 and initial clinical data for CNTY-813 expected in 2027. We are grateful for the high level of conviction and confidence shown by top investors focused on supporting development of our potential therapies for high-impact diseases, beginning with Type 1 diabetes.”

Pursuant to the terms of the securities purchase agreement, Century Therapeutics will issue approximately 117,391,299 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase 58,695,648 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) in the private placement at a purchase price of $1.15 per share and accompanying warrant to purchase 0.5 shares of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and at a purchase price of $1.1499 per pre-funded warrant and accompanying warrant to purchase 0.5 shares of common stock (or pre-funded warrant to purchase common stock in lieu thereof).

The pre-funded warrants will be exercisable immediately at an exercise price of $0.0001 per share and will not expire until exercised in full. The warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof) will be exercisable immediately upon issuance at an exercise price of $2.60 per share or $2.599 per pre-funded warrant and will expire upon the earlier of (a) 30 days after the public announcement of initial Phase 1 clinical data for CNTY-813 and (b) the third anniversary of the closing of the private placement. Full exercise of the warrants would provide an additional approximately $153 million in gross proceeds to the Company.

Century intends to use the net proceeds from the private placement to fund development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes.

The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (Securities Act), and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Century has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement and shares of common stock underlying the warrants issued in the private placement.

The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).

Leerink Partners, TD Cowen and Mizuho acted as the placement agents for the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares offered in the private placement, nor shall there be any sale of such shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding the satisfaction of customary closing conditions with respect to the private placement, our cash runway, anticipated clinical and development milestones and the anticipated use of proceeds of the private placement. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Century Therapeutics
Douglas Carr
Senior Vice President, Finance
investor.relations@centurytx.com

JPA Health
Sarah McCabe
smccabe@jpa.com

FAQ

How much did Century Therapeutics (IPSC) raise in the January 8, 2026 private placement?

Century expects initial gross proceeds of approximately $135 million from the private placement.

How does the IPSC financing affect Century Therapeutics' cash runway?

Management estimates the financing extends Century's cash runway to Q1 2029.

What securities were issued in the Century Therapeutics (IPSC) private placement and at what price?

Century will issue ~117,391,299 common shares (or pre-funded warrants) and warrants to buy ~58,695,648 shares at a purchase price of $1.15 per share with warrants exercisable at $2.60.

What is the potential additional funding if IPSC warrants are fully exercised?

Full exercise of the issued warrants would provide an additional approximately $153 million in gross proceeds.

What are the development milestones and timeline for CNTY-813 announced with the IPSC financing?

Century anticipates an IND submission in 2026 for CNTY-813 and initial clinical data in 2027.

When is the Century Therapeutics (IPSC) private placement expected to close?

The private placement is expected to close on January 9, 2026, subject to customary closing conditions.